Chris Buyse
Director/Board Member at INVENTIVA
Net worth: - $ as of 29/04/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Désiré Collen | M | - |
Life Sciences Research Partners VZW
Life Sciences Research Partners VZW Investment Trusts/Mutual FundsMiscellaneous Life Sciences Research Partners VZW functions as a foundation or endowment. The non-profit company is based in Leuven, Belgium. The Belgian company was founded by Désiré Collen. | 23 years |
Staf van Reet | M | - |
Intrexon ActoBiotics NV
Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | 5 years |
Pieter Rottiers | M | - |
Intrexon ActoBiotics NV
Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | 26 years |
Wim Goemaere | M | - |
Bio-Incubator Leuven
Bio-Incubator Leuven Real Estate DevelopmentFinance Bio-Incubator Leuven is a dynamic and innovative environment that provides lab space and support to R&D-intensive life sciences companies. The private company offers customizable modules that can be modified to meet the specific requirements of each client. The company is based in Leuven, Belgium. Leuven's knowledge institutes, including KU Leuven, University Hospitals Leuven, VIB, and IMEC, generate a huge outflow of knowledge that entails a myriad of innovative ideas for new and existing companies. The CEO of the Belgian company is Michaël de Blauwe. | 6 years |
Stijn van Rompay | M | 48 | 12 years | |
Thomas Jacobsen | M | 50 | 12 years | |
Frédéric Cren | M | 58 | 13 years | |
Jennifer Bath | M | - | 6 years | |
Pierre Broqua | M | 62 | 13 years | |
Etienne Marc Sokal | M | - |
Cellaïon SA
Cellaïon SA BiotechnologyHealth Technology Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation. | - |
Carolyn Myers | M | 66 |
EyeD Pharma SA
EyeD Pharma SA Medical SpecialtiesHealth Technology EyeD Pharma SA manufactures and supplies ophthalmology surgical products. Its products include R&D, instrumentation and phaco accessories. The company was founded by Jean-Marie Rakic and Jean-Michel Foidart and is headquartered in Liege, Belgium. | 4 years |
Jean-Luc Vandebroek | M | 53 | 3 years | |
Stéphane Vandervelde | M | - |
Creabuild NV
Creabuild NV Miscellaneous Commercial ServicesCommercial Services Creabuild NV provides consulting services. The private company is based in Zaventem, Belgium. The Belgian company was founded in 2005. The CEO is Stéphane Vandervelde.
Pinnacle Investments NV
| - |
Ann Dendoncker | F | - |
Sofia BVBA
Sofia BVBA Wireless TelecommunicationsCommunications Sofia BV provides wireless telecommunication services. The private company is based in Knokke-Heist, Belgium. The CEOs are Ann Dendoncker, Chris Buyse, Pieter-Jan Buyse. The Belgian company was founded in 1999.
Pienter-Jan BV
Pienter-Jan BV Miscellaneous Commercial ServicesCommercial Services Pienter-Jan BV is a Belgian company that provides business and management consulting services. The private company is based in Brasschaat, Belgium. The CEO of the company is Ann Dendoncker. | - |
Emil Pot | M | - |
Intrexon ActoBiotics NV
Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | 18 years |
Martine Zimmermann | M | 55 | 3 years | |
Heinz Christoph Mäusli | M | 61 | 5 years | |
Lothar Steidler | M | - |
Intrexon ActoBiotics NV
Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | - |
Alice Roudot-Ketelers | M | 53 | 3 years | |
Marc Foidart | M | - | 4 years | |
Annick Schwebig | M | 73 | 7 years | |
Magda van Hijfte | F | - |
Intrexon ActoBiotics NV
Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | 17 years |
Jean Volatier | M | 59 | 12 years | |
Mitchell Levine | M | - | - | |
Xiao Qin Lu | M | 49 | 6 years | |
Sven Watthy | M | - | - | |
Guido René van der Schueren | M | 72 |
Pinnacle Investments NV
Creabuild NV
Creabuild NV Miscellaneous Commercial ServicesCommercial Services Creabuild NV provides consulting services. The private company is based in Zaventem, Belgium. The Belgian company was founded in 2005. The CEO is Stéphane Vandervelde. | 4 years |
James Gale | M | 74 | 4 years | |
Louis Declerck | M | - |
Fund+
Fund+ Investment ManagersFinance Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium. | 5 years |
Eric Brandt | M | - |
EyeD Pharma SA
EyeD Pharma SA Medical SpecialtiesHealth Technology EyeD Pharma SA manufactures and supplies ophthalmology surgical products. Its products include R&D, instrumentation and phaco accessories. The company was founded by Jean-Marie Rakic and Jean-Michel Foidart and is headquartered in Liege, Belgium. | - |
Dietmar Aichhorn | M | - | 4 years | |
Michaël de Blauwe | M | - |
Bio-Incubator Leuven
Bio-Incubator Leuven Real Estate DevelopmentFinance Bio-Incubator Leuven is a dynamic and innovative environment that provides lab space and support to R&D-intensive life sciences companies. The private company offers customizable modules that can be modified to meet the specific requirements of each client. The company is based in Leuven, Belgium. Leuven's knowledge institutes, including KU Leuven, University Hospitals Leuven, VIB, and IMEC, generate a huge outflow of knowledge that entails a myriad of innovative ideas for new and existing companies. The CEO of the Belgian company is Michaël de Blauwe. | - |
Frederick Chabot | M | - | - | |
Pieter-Jan Buyse | M | - |
Sofia BVBA
Sofia BVBA Wireless TelecommunicationsCommunications Sofia BV provides wireless telecommunication services. The private company is based in Knokke-Heist, Belgium. The CEOs are Ann Dendoncker, Chris Buyse, Pieter-Jan Buyse. The Belgian company was founded in 1999. | 13 years |
Patrick van Beneden | M | 62 |
Intrexon ActoBiotics NV
Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | - |
Katrien Swerts | M | - |
Bio-Incubator Leuven
Bio-Incubator Leuven Real Estate DevelopmentFinance Bio-Incubator Leuven is a dynamic and innovative environment that provides lab space and support to R&D-intensive life sciences companies. The private company offers customizable modules that can be modified to meet the specific requirements of each client. The company is based in Leuven, Belgium. Leuven's knowledge institutes, including KU Leuven, University Hospitals Leuven, VIB, and IMEC, generate a huge outflow of knowledge that entails a myriad of innovative ideas for new and existing companies. The CEO of the Belgian company is Michaël de Blauwe. | - |
Eric Pauly | M | - |
Cellaïon SA
Cellaïon SA BiotechnologyHealth Technology Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation. | 2 years |
Ilse Roodink | M | - | 3 years | |
Barry Duplantis | M | - | - | |
Peter Verhamme | M | - |
Life Sciences Research Partners VZW
Life Sciences Research Partners VZW Investment Trusts/Mutual FundsMiscellaneous Life Sciences Research Partners VZW functions as a foundation or endowment. The non-profit company is based in Leuven, Belgium. The Belgian company was founded by Désiré Collen. | - |
Rutul Shah | M | - |
Intrexon ActoBiotics NV
Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | - |
Donald Lehr | M | - |
Intrexon ActoBiotics NV
Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | - |
Caroline Thielen | M | - |
Cellaïon SA
Cellaïon SA BiotechnologyHealth Technology Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation. | - |
Sam Corveleyn | M | - |
Intrexon ActoBiotics NV
Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | - |
Daan Hommes | M | - |
Intrexon ActoBiotics NV
Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | - |
Marc Waer | M | - |
Fund+
Fund+ Investment ManagersFinance Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium. | - |
Dirk Witters | M | - | 1 years | |
Barry Springer | M | - | 1 years | |
Mélanie Mestdagt | F | - |
EyeD Pharma SA
EyeD Pharma SA Medical SpecialtiesHealth Technology EyeD Pharma SA manufactures and supplies ophthalmology surgical products. Its products include R&D, instrumentation and phaco accessories. The company was founded by Jean-Marie Rakic and Jean-Michel Foidart and is headquartered in Liege, Belgium. | 11 years |
Denis Knoops | M | - |
EyeD Pharma SA
EyeD Pharma SA Medical SpecialtiesHealth Technology EyeD Pharma SA manufactures and supplies ophthalmology surgical products. Its products include R&D, instrumentation and phaco accessories. The company was founded by Jean-Marie Rakic and Jean-Michel Foidart and is headquartered in Liege, Belgium. | - |
Kari Graber | F | - | - | |
Mounia Chaoui-Roulleau | M | 52 |
Intrexon ActoBiotics NV
Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | - |
Jos Sluys | M | 61 |
Intrexon ActoBiotics NV
Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | - |
David Nikodem | M | 54 | 6 years | |
Leon van Rompay | M | 75 | 4 years | |
Johan Cardoen | M | 65 |
Intrexon ActoBiotics NV
Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | - |
Nicolas Jacques Boël | M | 62 |
Fondation Francqui
| - |
Pierre de Waha | M | - |
Cellaïon SA
Cellaïon SA BiotechnologyHealth Technology Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation. | - |
Jean van Nuwenborg | M | - |
EyeD Pharma SA
EyeD Pharma SA Medical SpecialtiesHealth Technology EyeD Pharma SA manufactures and supplies ophthalmology surgical products. Its products include R&D, instrumentation and phaco accessories. The company was founded by Jean-Marie Rakic and Jean-Michel Foidart and is headquartered in Liege, Belgium. | - |
Sabine Neirynck | M | - |
Intrexon ActoBiotics NV
Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | 18 years |
Stefan Yee | M | 62 | 5 years | |
Jan Delcour | M | - |
Bio-Incubator Leuven
Bio-Incubator Leuven Real Estate DevelopmentFinance Bio-Incubator Leuven is a dynamic and innovative environment that provides lab space and support to R&D-intensive life sciences companies. The private company offers customizable modules that can be modified to meet the specific requirements of each client. The company is based in Leuven, Belgium. Leuven's knowledge institutes, including KU Leuven, University Hospitals Leuven, VIB, and IMEC, generate a huge outflow of knowledge that entails a myriad of innovative ideas for new and existing companies. The CEO of the Belgian company is Michaël de Blauwe. | - |
Decebal Bora | M | - |
Intrexon ActoBiotics NV
Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | 17 years |
Koenraad van der Elst | M | 63 | 4 years | |
Eric Marie Albert Duranson | M | 50 | 3 years | |
Françoise Masai | M | 77 |
Fondation Francqui
| 15 years |
Andy de Deene | M | - | 16 years | |
Philippe Monteyne | M | - |
Fund+
Fund+ Investment ManagersFinance Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium. | 9 years |
Paul Deleu | M | 64 |
Bio-Incubator Leuven
Bio-Incubator Leuven Real Estate DevelopmentFinance Bio-Incubator Leuven is a dynamic and innovative environment that provides lab space and support to R&D-intensive life sciences companies. The private company offers customizable modules that can be modified to meet the specific requirements of each client. The company is based in Leuven, Belgium. Leuven's knowledge institutes, including KU Leuven, University Hospitals Leuven, VIB, and IMEC, generate a huge outflow of knowledge that entails a myriad of innovative ideas for new and existing companies. The CEO of the Belgian company is Michaël de Blauwe. | - |
Alexandra Tolia | M | - |
Fund+
Fund+ Investment ManagersFinance Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium. | 6 years |
Johan Bohets | M | 52 |
Pinnacle Investments NV
| - |
Alain Hubert | M | - | 11 years | |
Fouzia Laghrissi-Thodes | M | 61 |
Cellaïon SA
Cellaïon SA BiotechnologyHealth Technology Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation. | - |
Benoit Fellin | M | - |
EyeD Pharma SA
EyeD Pharma SA Medical SpecialtiesHealth Technology EyeD Pharma SA manufactures and supplies ophthalmology surgical products. Its products include R&D, instrumentation and phaco accessories. The company was founded by Jean-Marie Rakic and Jean-Michel Foidart and is headquartered in Liege, Belgium. | - |
Michael P. Cooreman | M | 66 | 4 years | |
Nathalie Harroy | F | 57 | 12 years | |
Kristin Taylor | F | - | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Thomas Lienard | M | 48 | 5 years | |
Paul Magrez | M | - |
Fund+
Fund+ Investment ManagersFinance Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium. | 3 years |
Patrik de Haes | M | - | 15 years | |
Thomas Moragne Clay | M | 39 | 12 years | |
Cécile Galle | M | - | - | |
Landon Clay | M | 98 | - | |
Patricia Ceysens | F | - | 8 years | |
Nawal Ouzren | F | 45 | - | |
Dirk Dembski | M | - | 2 years | |
Steven Swinson | M | - | 1 years | |
Philippe Pierre Goupit | M | - | 2 years | |
Patrick van den Eynde | M | 61 |
University of Antwerp
| 4 years |
Karen Pignet-Aiach | F | 52 | - | |
Thierry François | M | - | - | |
Valérie Gangji | M | - | - | |
Claudia D'Augusta | M | 54 | - | |
Damian Marron | M | 62 | - | |
Jean-Louis Abitbol | M | - | - | |
Christopher Gregory Newton | M | 68 | - | |
Marc Nolet de Brauwere | M | - | 2 years | |
Baron Jean Stéphenne | M | 73 | - | |
Gregory Smith | M | 57 | 7 years | |
Krisja Vermeylen | F | 62 |
University of Antwerp
| 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
Belgium | 73 | 73.00% |
France | 17 | 17.00% |
Canada | 10 | 10.00% |
United States | 0 | -.--% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Chris Buyse
- Personal Network